6 Questions to Ask Your Doctor Before Starting a Mental-Health Drug Time Magazine
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting BioSpace
Scientists Say Common Meds May Raise Mortality Risk in People With IBS Prevention
CAPLYTA® showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis Investing News Network
Finding new ways to mimic ketamine’s antidepressant effects News-Medical
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting FinancialContent
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting Business Wire
Tiny Brain Cells Hold the Key to Faster, Safer Antidepressants ScienceBlog.com
How Scientists Cracked the Ketamine Code for Depression Neuroscience News
